Author:
Kawatsu Lisa,Kaneko Noriyo,Imahashi Mayumi,Kamada Keisuke,Uchimura Kazuhiro
Abstract
Abstract
Background
Tuberculosis (TB) continues to be the leading cause of death for people living with HIV/AIDS (PLHIV), and HIV is the strongest known risk factor for progression to active TB disease for persons with latent TB infection (LTBI). Screening for active TB and LTBI, and TB preventive therapy (TPT) is recommended, however, clinical practices regarding LTBI screening for HIV positive population have not been uniform, resulting in low rates of LTBI screening and TPT uptake, in both low and high TB-burden countries. We sought to explore the practices and attitudes towards TB and LTBI screening in PLHIV among HIV physicians in Japan.
Methods
We conducted a cross-sectional survey whereby an on-line questionnaire was administered to physicians who are currently, or have the experience of, providing care and treatment for PLHIV in Japan.
Results
The questionnaire was sent to a total of 83 physicians, of which 59 responded (response rate; 71.1%). 52.5% (31/59) conducted routine screening and 44.0% (26/59) conducted selectively screening for active TB among HIV/AIDS patients. As for LTBI, 54.2% (32/59) conducted routine screening and 35.6% (21/59) conducted selective screening for LTBI among PLHIV. “T-SPOT only” was the most frequently used method of screening (n = 33), followed by “QFT only” (n = 11). Criteria for LTBI screening included TB burden in the country of birth of the patient, previous contact with a TB patient, and CD4+ cell count. 83.1% (49/59) either “always” or “selectively” offered TPT to PLHIV diagnosed with LTBI, and among the 49 respondents who did provide TPT, 77.6% (38/49) chose 9-months isoniazid as their first choice. None chose regimen including rifampicin.
Conclusions
Our study revealed that practices regarding TB and LTBI screening and treatment for PLHIV among HIV physicians were mixed and not necessarily in accordance with the various published guidelines. Building and disseminating scientific evidence that takes into consideration the local epidemiology of TB and HIV in Japan is urgently needed to assist physicians make decisions.
Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Virology,Molecular Medicine
Reference44 articles.
1. Tuberculosis and HIV—progress towards the 2020 target. Geneva: Joint United Nations Programme on HIV/AIDS; 2019. https://www.unaids.org/en/resources/documents/2019/tuberculosis-and-hiv-progress-towards-the-2020-target. Accessed 20 Oct 2021.
2. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. License: CC BY-NC-SA 3.0 IGO.
3. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29:1987–2002.
4. Tuberculosis Surveillance Center. Tuberculosis in Japan—annual report 2022. Tokyo: Research Institute of Tuberculosis; 2022. https://jata-ekigaku.jp/english/tb-in-japan. Accessed 1 Nov 2022.
5. AIDS surveillance committee. Annual AIDS Report 2021. Tokyo: Ministry of Health, Labour and Welfare; 2022. https://api-net.jfap.or.jp/status/japan/nenpo.html. Accessed 25 Oct 2021.